Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
Adami
Fausto
F
Briani
Chiara
C
Binotto
Gianni
G
Altinier
Sara
S
Tarantini
Giuseppe
G
Semenzato
Gianpietro
G
D000686:Amyloidosis / Q000097:blood* / Q000188:drug therapy*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood*; D003907:Dexamethasone / Q000008:administration & dosage*; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D008991:Monitoring, Physiologic; D016878:POEMS Syndrome / Q000097:blood* / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D007147:Immunoglobulin Light Chains; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D003907:Dexamethasone; D008558:Melphalan